Wave Life Sciences (WVE) Total Liabilities (2014 - 2026)
Wave Life Sciences' (WVE) quarterly Total Liabilities came in at $104.8 million in Q2 2026, little changed YoY from $105.2 million in Q2 2025, and up 45.93% on a QoQ basis from $71.8 million in Q1 2026.
Wave Life Sciences (WVE) Total Liabilities (2014 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 13 years of Total Liabilities data on file, last reported at $104.8 million in Q2 2026.
- Quarterly Total Liabilities changed 0.39% year-over-year to $104.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $104.8 million (changed 0.39% YoY) and the FY2025 annual result came in at $112.3 million, down 16.73% from the prior year.
- Total Liabilities grew to $104.8 million in Q2 2026, from $71.8 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $294.1 million in Q1 2023 to a low of $71.8 million in Q1 2026.
- A 5-year average of $171.4 million and a median of $176.3 million in 2022 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2023 — Total Liabilities jumped 84.35% — and 2025, when it sank 48.53%.
- Tracing WVE's Total Liabilities over 5 years: stood at $183.6 million in 2022, then advanced by 23.88% to $227.4 million in 2023, then slumped by 40.73% to $134.8 million in 2024, then retreated by 16.73% to $112.3 million in 2025, then slipped by 6.65% to $104.8 million in 2026.
- The last three Total Liabilities figures came in at $104.8 million (Q2 2026), $71.8 million (Q1 2026), and $112.3 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Wave Life Sciences | 1.05 Bn | 677.62 Mn | - | 104.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 104.80 Mn |
| Mar 31, 2026 | 71.81 Mn |
| Dec 31, 2025 | 112.27 Mn |
| Sep 30, 2025 | 108.96 Mn |
| Jun 30, 2025 | 105.22 Mn |
| Mar 31, 2025 | 108.67 Mn |
| Dec 31, 2024 | 134.82 Mn |
| Sep 30, 2024 | 208.99 Mn |
| Jun 30, 2024 | 204.42 Mn |
| Mar 31, 2024 | 202.01 Mn |
| Dec 31, 2023 | 227.45 Mn |
| Sep 30, 2023 | 232.53 Mn |
| Jun 30, 2023 | 273.83 Mn |
| Mar 31, 2023 | 294.11 Mn |
| Dec 31, 2022 | 183.60 Mn |
| Sep 30, 2022 | 178.16 Mn |
| Jun 30, 2022 | 174.50 Mn |
| Mar 31, 2022 | 159.54 Mn |
| Dec 31, 2021 | 166.64 Mn |
| Sep 30, 2021 | 162.74 Mn |